INTRODUCTION {#sec0001}
============

In recent years, advances in genetic interrogation of patient samples have led to discovery of several novel genes that underlie inherited bone marrow failure and myelodysplastic syndrome (MDS) [@bib0001]. These include *SAMD9* (sterile α-motif domain-containing protein 9) and *SAMD9L* (*SAMD9-like*) genes, located head to tail on chromosome 7q21.2 in a region that is frequently deleted in myeloid malignancies [@bib0002], [@bib0003].

Germline mutations in *SAMD9* and *SAMD9L* cause the multisystem disorders, MIRAGE (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy) and ataxia-pancytopenia syndromes, respectively [@bib0004], [@bib0005], [@bib0006]. Recent studies in children reported a rate of *SAMD9* and *SAMD9L* mutations in 18.6% and 17% cases with suspected inherited bone marrow failure syndromes and those with primary MDS, respectively [@bib0007], [@bib0008].

SAMD9 and SAMD9L proteins are involved in endosomal trafficking and negatively regulate cell proliferation [@bib0009]. Gain-of-function heterozygous mutations in these genes lead to cellular growth restriction and hypoplasia, resulting in cytopenias, bone marrow failure, and immunodeficiency. Interestingly, in many cases, there is a nonrandom loss of the mutated allele via full or partial deletion of chromosome 7 [@bib0004], [@bib0010], [@bib0011], [@bib0012]. The resultant monosomy 7 or deletion 7q can result in the development of MDS and acute myeloid leukemia (AML) [@bib0008], [@bib0011], [@bib0012]. Conversely, other "genetic correction" events such as in *cis* missense, nonsense, or loss of heterozygosity through uniparental disomy can result in normal hematopoiesis.

Since the initial report of MIRAGE syndrome in 2016, a series of studies has described clinical and genetic findings in patients and families with *SAMD9/SAMD9L* mutations [@bib0007], [@bib0011], [@bib0013]. Hematopoietic cell transplantation (HCT) therapy has been included in some reports, but transplantation details are lacking. A recent article by Sarthy et al. [@bib0014] documented 2 children with MIRAGE syndrome who succumbed to post-transplant complications due to syndrome-related comorbidities. We aimed to obtain a more complete assessment of transplant outcomes and the challenges and complications encountered in these patients.

METHODS {#sec0002}
=======

After management of 2 cases with MIRAGE syndrome, additional cases were identified by literature search and peer consultations. For inclusion, patients were required to have a confirmed heterozygous mutation in the *SAMD9* or *SAMD9L* gene and a minimum of 1-year follow-up post-transplant. Deidentified data for each case were collected by using a standardized questionnaire. All studies involving human subjects were performed in accordance with site-specific protocols approved by the institutional review board and in accordance with Declaration of Helsinki guidelines.

The primary study endpoints were overall survival and event-free survival. Safety and tolerability of HCT and impact of pretransplant comorbidities were evaluated by occurrence and severity of post-transplant complications, need for life support measures, and risk of transplant-related mortality. Transplant outcomes were defined using Center for International Blood and Marrow Transplant Research criteria [@bib0015]. Grading of acute graft-versus-host disease (GVHD) and diagnosis of chronic GVHD were based on standard criteria [@bib0016]. Surviving patients were censored at last follow-up. Continuous variables were summarized as median and range of values and analyzed using the Mann-Whitney test. Survival curves were generated using the Kaplan-Meier method and compared using the log-rank (Mantel-Cox) test using the GraphPad Prism 7 software (GraphPad Software, San Diego, CA).

RESULTS {#sec0003}
=======

Twelve patients underwent allogeneic HCT for hematologic disorders associated with germline *SAMD9* (n = 6) or *SAMD9L* (n = 6) mutations ([Table 1](#tbl0001){ref-type="table"} ). Patients 3, 4, 6, 11, and 12 ([Table 1](#tbl0001){ref-type="table"}) were included in previous reports [@bib0011], [@bib0013], [@bib0017]. Indication for transplant was MDS in 10 of 12 (83%) cases. One *SAMD9* patient with markedly reduced megakaryocytic precursors in marrow underwent transplantation for a presumed diagnosis of congenital amegakaryocytic thrombocytopenia, and 1 patient with *SAMD9L* mutation and shortened telomeres underwent transplantation on a presumed diagnosis of dyskeratosis congenita.Table 1Patient CharacteristicsTable 1Patient No.12345Age at initial presentation, years0.1713.14.80.8GenderMMFMFRace/EthnicityHispanicCaucasianCaucasianCaucasianAfrican AmericanGene mutation*SAMD9* c.2471G\>A; pR824Q*SAMD9* c.4690G\>A; p.G1564S*SAMD9* c.3406G\>C; p.E1136Q*SAMD9* c.3406G\>C p.E1136Q*SAMD9* c.2407 G\>C; p.E803QFamily member with same gene mutationParents negativeParents negativePatient no. 3 and 4 in this report, a younger sibling and their mother positivePatient no. 3 and 4 in this report, a younger sibling and their mother positiveParents negativeMIRAGE syndrome features (*SAMD9* cases)Infections, restriction of growth, adrenal, genital, enteropathyMDS, infections, restriction of growth, adrenal, enteropathyMDSMDS, genitalMDS, infections, restriction of growth, enteropathyOther clinical findingsNewborn Period: Born at 29 weeks, birth weight 982 grams, mechanical ventilation. Chronic lung disease of prematurity. Microcephaly, developmental delay, panhypopituitarism, laryngeal cleft, intussusception, FSGSNewborn Period: Born at 34 weeks, birth weight 1425 grams, no mechanical ventilation. Achalasia of esophagus, developmental delay----Newborn Period: Born at 36 weeks, birth weight 1895 grams, no mechanical ventilation. Staphylococcal sepsis with respiratory failure. Developmental delayHematologyThrombocytopenia followed by pancytopenia. Hypocellular marrow, megakaryocytic hypoplasiaPancytopenia. Hypocellular marrow, reduced megakaryocytes and dysplasiaThrombocytopenia. Hypocellular marrow, trilineage dysplasiaHypocellular marrow, trilineage dysplasia, refractory cytopenia of childhoodPancytopenia. Normocellular marrow, megakaryocytic dysplasiaChromosome 7Somatic mosaic monosomy 7, somatic mosaic chr. 7q deletion, UPD chr. 7Somatic mosaic monosomy 7, somatic mosaic 7q31 deletion, UPD chr. 7Monosomy 7Somatic mosaic monosomy 7Somatic mosaic monosomy 7Patient No.678910Age at initial presentation, years2.312.60.98.10.7GenderMFMFMRace/EthnicityCaucasianHispanicHispanicCaucasianAfrican AmericanGene mutation*SAMD9* c.2318T\>C; p.I773T*SAMD9L* c.1877C\>T; p.S626L*SAMD9L* c.1877C\>T; p.S626L*SAMD9L* c.3538T\>C; p.W1180R*SAMD9L* c.4651 G\>C; p.V1551LFamily member with same gene mutationMother negative, father unavailablePatients no. 7 and 8 in this report are nephews. Parents not tested. A maternal aunt is positivePatients no. 7 and 8 in this report are nephews. Parents not tested. A maternal aunt is positiveParents not testedParents negativeMIRAGE syndrome features (*SAMD9* cases)MDS, infections, restriction of growth, adrenal, genital, enteropathyN.A.N.A.N.A.N.A.Other clinical findingsNewborn Period: Born at 34 weeks, birth weight 1853 grams, no mechanical ventilation. FSGS, short telomeres. microcephaly, hypotelorism, strabismus, beaked nose, reactive airway disease, warts----HypogammaglobulinemiaHLH. SepsisHematologyThrombocytopenia. Hypocellular marrow, dysplastic megakaryocytesHypocellular marrow, dyserythropoiesisHypocellular marrow, dyserythropoiesis and dysmegakaryopoiesisHypocellular marrow, atypical megakaryocytesPancytopenia. Hypocellular marrow, dyserythropoiesis, dysgranulopoiesisChromosome 7Mosaic chr. 7q deletionAbsence of heterozygosity chr. 7q (myeloid)Mosaic monosomy 7Mosaic monosomy 7Mosaic monosomy 7Patient No.1112Age at initial presentation, years1.61.3GenderFMRace/EthnicityCaucasianCaucasianGene mutation*SAMD9L* c.2957G\>A; p.R986H*SAMD9L* c.2957G\>A; p.R986HFamily member with same gene mutationPatients no. 11 and 12 in this report are siblings. Father positive. Mother negativePatients no. 11 and 12 in this report are siblings. Father positive. Mother negativeMIRAGE syndrome features (*SAMD9* cases)N.A.N.A.Other clinical findingsEczemaEczemaHematologyThrombocytopenia followed by pancytopenia. Normocellular marrow with dysplasiaPancytopenia. Normocellular marrow with megakaryocyte dysplasiaChromosome 7Mosaic monosomy 7Mosaic monosomy 7, mosaic chr. 7q deletion[^1]

Median age at presentation for patients with *SAMD9* mutations (1.65 years; range, 0.17 to 4.8 years) was similar to those with *SAMD9L* mutations (1.43 years; range, 0.67 to 12.6 years). Six patients had pancytopenia, including 5 with thrombocytopenia and 1 with anemia. Bone marrow was hypocellular in 11 (92%) cases and showed dysplasia most prominently in the megakaryocytic lineage in most cases. Chromosome 7 abnormalities, including monosomy 7 and chromosome 7q deletions, were present in all cases. All except 1 case showed somatic mosaicism for chromosome 7 abnormalities (ie, detection of a monosomy 7 or chromosome 7 deletion clone in only a fraction of hematopoietic cells in bone marrow).

Exome sequencing revealed 5 different missense heterozygous mutations in the 6 *SAMD9* cases and 4 different missense mutations in the 6 *SAMD9L* cases. Their genomic details and pathogenicity assessment of variants are summarized in [Table 2](#tbl0002){ref-type="table"} and cross-referenced [@bib0005], [@bib0007], [@bib0008], [@bib0012], [@bib0013], [@bib0017], [@bib0018], [@bib0019], [@bib0020]. Six of 12 cases were familial. Four *SAMD9* patients had phenotypic features of MIRAGE syndrome (patients 1, 2, 5, and 6; [Tables 1](#tbl0001){ref-type="table"} and [2](#tbl0002){ref-type="table"}); unique findings included panhypopituitarism, laryngeal cleft, and glomerulosclerosis. Two other cases with a *SAMD9* mutation had milder phenotypes with growth restriction in 1 and hypospadias and a bifid scrotum in another. The remaining patients had no phenotypic abnormalities.Table 2Pathogenicity Assessment of Observed *SAMD9* and *SAMD9L* VariantsTable 2Patient No.12345Gene and Variant*SAMD9*. Heterozygous c.2471G\>A (p.Arg824Gln)*SAMD9.* Heterozygous c.4690G\>A (p.G1564S)*SAMD9.* Heterozygous c.3406G\>C (p.E1136Q)*SAMD9.* Heterozygous c.3406G\>C (p.E1136Q)*SAMD9.* Heterozygous c.2407 G\>C (p.E803Q)Method of genetic diagnosisWES confirmed by Sanger sequencingWES confirmed by Sanger sequencingWES and WGS, targeted Sanger sequencing of parentWES and WGS, targeted Sanger sequencing of parentWES confirmed by Sanger sequencing*SAMD9 / SAMD9L* variant: *De novo* status*De novo* (parentage confirmed)Since parents negative, this should be *de novo,* but parentage not confirmedNot *de novo*Not *de novoDe novo* (parentage confirmed)Germline sourceKidney--Sorted lymphocytesSorted lymphocytes--Family tested for the same variantSibling donor was not tested prior to BMT since the *SAMD9* variant was discovered in the recipient afterwards. Parents subsequently tested and were negative.Parents negativePatient no. 3 and 4 in this report, a younger sibling and their mother positive. The younger sibling had transient thrombocytopenia at birth requiring platelet transfusion.Patient no. 3 and 4 in this report, a younger sibling and their mother positive. The younger sibling had transient thrombocytopenia at birth requiring platelet transfusion.Parents negativeACMG[⁎](#tb2fn1){ref-type="table-fn"} classificationPathogenicLikely PathogenicVUS (Potentially Pathogenic[†](#tb2fn2){ref-type="table-fn"})VUS (Potentially Pathogenic[†](#tb2fn2){ref-type="table-fn"})Likely PathogenicHow pathogenicity was ascribedPS2 -- *de novo*, parentage confirmed\
PS3 -- functional study supports damaging effect\
PM2 -- absent from controlsPM2 -- absent from controls\
PM6 -- assumed *de novo*\
PP3 -- *in silico* prediction: deleterious\
PP4 -- UPD7 together with MIRAGE featuresPS3 -- functional study supports damaging effect\
PM2 -- absent from controls\
BS4 -- lack of segregation in family membersPS3 -- functional study supports damaging effect\
PM2 -- absent from controls\
BS4 -- lack of segregation in family membersPS2 -- *de novo*, parentage confirmed\
PM2 -- absent from controlsReferencesJeffries et al. [@bib0018]Not found via literature searchSchwartz et al, [@bib0008] (Leukemia), Schwartz et al, [@bib0013] (Nat Comm)Schwartz et al, [@bib0008] (Leukemia), Schwartz et al, [@bib0013] (Nat Comm)Not found via literature searchPatient No.678910Gene and Variant*SAMD9*. Heterozygous c.2318T\>C (p.**I**773T)*SAMD9L.* Heterozygous c.1877C\>T; p.S626L*SAMD9L.* Heterozygous c.1877C\>T (p.S626L)*SAMD9L.* Heterozygous c.3538T\>C (p.W1180R)*SAMD9L.* Heterozygous c.4651 G\>C (p.V1551L)Method of genetic diagnosisWES confirmed by Sanger sequencingWES confirmed by Sanger sequencingWES confirmed by Sanger sequencingWES confirmed by Sanger sequencingWES confirmed by Sanger sequencing*SAMD9 / SAMD9L* variant: *De novo* status*De novo* status not known since dad not testedParents not tested. Aunt has the same variant.\
*De novo* status not known.Parents not tested. Aunt has the same variant. *De novo* status not known.Parents not tested*. De novo* status not known.*De novo* (parentage confirmed)Germline source--------Skin fibroblastsFamily tested for the same variantMother tested and was negative. Dad unavailable for testingPatients no. 7 and 8 in this report are nephews. A maternal aunt with cytopenias and confirmed *SAMD9L* mutation (parents not tested for *SAMD9*/*SAMD9L*), brother with cytopenias (not tested).Patients no. 7 and 8 in this report are nephews. A maternal aunt with cytopenias and confirmed *SAMD9L* mutation (parents not tested for *SAMD9*/*SAMD9L*), brother with cytopenias (not tested).Parents not testedParents negativeACMG[⁎](#tb2fn1){ref-type="table-fn"} classificationVUSLikely PathogenicLikely PathogenicLikely PathogenicPathogenicHow pathogenicity was ascribedPM2 - absent from controls\
PP4 -- subclonal 7q deletion together with MIRAGE featuresPS3 -- functional study supports damaging effect\
PM2 -- absent from controls\
PP1 -- segregates with affected family membersPS3 -- functional study supports damaging effect\
PM2 -- absent from controls\
PP1 -- segregates with affected family membersPS3 -- functional study supports damaging effect\
PM2 -- absent from controlsPS2 -- de novo\
PS3 -- functional study supports damaging effect\
PM2 -- absent from controlsReferencesPerisa et al, [@bib0017]Schwartz et al, [@bib0008] (Nat Comm)Schwartz et al, [@bib0008] (Nat Comm)Schwartz et al, [@bib0008] (Nat Comm)Ortolano et al, [@bib0019]Patient No.1112Gene and Variant*SAMD9L*. Heterozygous c.2957G\>A (p.R986H)*SAMD9L*. Heterozygous c.2957G\>A (p.R986H)Method of genetic diagnosisSanger sequencing of peripheral blood. Confirmed by Sanger sequencing of hair folliclesTargeted NGS. Confirmed by Sanger sequencing of hair follicles*SAMD9 / SAMD9L* variant: *De novo* statusNot *de novo*Not *de novo*Germline sourceHair folliclesHair folliclesFamily tested for the same variantPatients no. 11 and 12 in this report are siblings. Father positive. Mother negative.Patients no. 11 and 12 in this report are siblings. Father positive. Mother negative.ACMG[⁎](#tb2fn1){ref-type="table-fn"} classificationLikely PathogenicLikely PathogenicHow pathogenicity was ascribedPS3 -- functional study supports damaging effect\
PM5 -- another variant (p.R986C) at the same position is pathogenicPS3 -- functional study supports damaging effect\
PM5 -- another variant (p.R986C) at the same position is pathogenicReferencesTesi et al, [@bib0005]; Bluteau et al, [@bib0007]; Wong et al, [@bib0012]Tesi et al, [@bib0005]; Bluteau et al, [@bib0007]; Wong et al, [@bib0012][^2][^3][^4]

Transplant details of individual cases are summarized in [Table 3](#tbl0003){ref-type="table"}. Median age at HCT was 2.8 years (range, 1.16 to 12.8 years). Median age at HCT tended to be higher in *SAMD9* patients versus *SAMD9L* patients at 4.15 years versus 2.2 years, respectively (*P* = .81). Median time from initial presentation to transplant was 0.45 years (range, 0.2 to 6.53 years). There was an interval of 5.5 and 6.53 years from initial diagnosis to HCT in 2 cases of MIRAGE syndrome because in these cases, blood counts seemed to show improvement before patients developed sustained marrow failure. Stem cell sources included bone marrow (matched unrelated, n = 7; HLA identical sibling, n = 2; and haploidentical parent, n = 1) and unrelated cord blood (n = 2). Nine patients received myeloablative conditioning (busulfan based, n = 7, or total-body irradiation based, n = 2). Three patients received reduced-intensity conditioning with fludarabine, cyclophosphamide, or melphalan, with rabbit antithymocyte globulin or alemtuzumab.

Clinically significant pretransplant comorbidities were present in *SAMD9* cases with MIRAGE syndrome ([Table 3](#tbl0003){ref-type="table"} ). These included chronic diarrhea, electrolyte imbalance, infections, adrenal insufficiency, failure to thrive, lung disease, and renal dysfunction. One patient with *SAMD9L* mutation (patient 10, [Table 2](#tbl0002){ref-type="table"} and [Table 3](#tbl0003){ref-type="table"}) had been treated for hemophagocytic lymphohistiocytosis, disseminated sepsis, invasive fungal infections before transplant.Table 3Transplant Characteristics and OutcomesTable 3Patient No.12345Gene involved*SAMD9* (MIRAGE syndrome)*SAMD9* (MIRAGE syndrome)*SAMD9SAMD9SAMD9* (MIRAGE syndrome)Age at HCT, years6.71.43.351.2Interval from diagnosis to HCT, years6.50.40.20.20.4Indication for HCTPresumed congenital amegakaryocytic thrombocytopeniaMDSMDSMDSMDSSignificant pretransplant issuesSecretory diarrhea, adrenocortical insufficiency, lung disease, CKD, failure to thriveEsophageal achalasia, gastroesophageal reflux, diarrhea, failure to thrive----Diarrhea. Failure to thrive.Donor typeHLA-identical sibling, female, bone marrowUnrelated, 10/10 allele match, male, bone marrowUnrelated, 8/8 allele match, female, bone marrowUnrelated, 8/8 allele match, male, bone marrowFather, 5/10 allele match, bone marrowConditioning regimen; GVHD prophylaxisFlu/Cy/ATG; Tac/MMFBu/Flu/ATG; Tac/MtxBu/Cy/ATG; CsA/MtxBu/Cy/ATG; CsA/MtxBu/Flu; posttransplant Cy, Tac/MMFConditioning intensity (MA / RIC)RICMAMAMAMANeutrophil engraftment, days+1312161914Platelet engraftment, days+1630141540Posttransplant courseTemperature & blood pressure instability, electrolyte imbalance, dehydration, hypoxiaTMA, recurrent pericardial effusions, hypoxiaVOD of liverPericardial effusionTMA, pericardial effusion, VOD of liverIntensive careSevere hypertensionNoRespiratory distress, did not require intubationRespiratory distress, required intubationRespiratory failure, did not require intubationAcute GVHD / Chronic GVHDNo / NoNo / YesNo / NoNo / NoNo / NoChimerism99% donor100% donor100% donor99% donor100% donorPost-HCT hematologic outcomeNormal blood counts, no monosomy 7Normal blood counts, no monosomy 7, resolution of MDSResolution of MDS, no chr. 7 findingResolution of MDS, no chr. 7 findingsNormal blood counts, no monosomy 7, resolution of MDSSurvival statusAlive; 2.4 y post-HCTAlive; 3.8 y post-HCTAlive; 3.2 y post-HCTAlive; 3 y post-HCTAlive; 1.4 y post-HCTCurrent health statusSecretory diarrhea, enteral feeds, low weight and height, thriving, developmental delay, CKD, hypertension, adrenal insufficiencyRecurrent aspiration pneumonias, chronic lung disease, malnutrition, diarrhea, developmental delay, thriving, adrenal insufficiencySchool performance issuesLearning disabilitiesSupplemental feeds, hypoglycemia episodes, diarrhea, low weight and height, thriving, developmentally delayPatient No.678910Gene involved*SAMD9* (MIRAGE syndrome)*SAMD9LSAMD9LSAMD9LSAMD9L*Age at HCT, years7.812.82.38.32Interval from diagnosis to HCT, years5.50.21.40.21.3Indication for HCTMDSPresumed dyskeratosis congenitaMDSMDSMDSSignificant pretransplant issuesHypertension, chronic kidney disease, asthmaObesity (BMI 34, \>97th percentile for age)Obesity (BMI 27, \>97th percentile for age)--HLH therapy. E. coli sepsis, pancolitis, ecthyma gangrenosum, aspergillus and candida sepsisDonor typeUnrelated, 10/10 allele match, male, bone marrowUnrelated double cord blood, male (5/6 allele match), female (5/6 allele match)Unrelated cord blood, 6/6 allele match, femaleHLA-identical sibling, female, bone marrowUnrelated, 9/10 allele match, bone marrowConditioning regimen; GVHD prophylaxisFlu/Mel/Alemtuzumab; Tac/MMFFlu/Mel/Alemtuzumab; Tac/MMFFlu/Cy/TBI; CsA/MMFCy/TBI/Ara-CBu/Cy/ATGConditioning intensity (MA / RIC)RICRICMAMAMANeutrophil engraftment, days+19No131718Platelet engraftment, days+19No1231NoPosttransplant courseBlood pressure instability, electrolyte imbalance, fevers, hypoxiaRestrictive lung diseaseParainfluenza with respiratory failure, renal dysfunctionCulture negative sepsis, bleeding gastric ulcer, hemorrhagic cystitisCoronavirus respiratory tract infection, VOD of liver with respiratory failure, defibrotide, diffuse alveolar hemorrhageIntensive careNoNoRespiratory failureSystemic inflammatory response syndromeRespiratory failure, required intubationAcute GVHD / Chronic GVHDNo / NoNo / NoYes (Grade II, GI, resolved)/NoNo / NoNot evaluable / Not evaluableChimerism98% donor0% donor99% donor100% donorNot donePost-HCT hematologic outcomeNormal blood countsGraft failureResolution of MDS, no chr. 7 findingResolution of MDS, no chr. 7 findingNeutrophil engraftment. Bone marrow not assessedSurvival statusAlive; 4.1 y post-HCTDied of refractory AML; 1.1 y post-HCTAlive; 2.3 y post-HCTAlive; 14.7 y post-HCTDied at day +23 post-HCT from complications related to VOD of liverCurrent health statusAdrenal insufficiency, diarrhea, hypotension, CKD, urethrocutaneous fistula, developmental delay, thrivingN.A.CKDDoing wellN.A.Patient No.1112Gene involved*SAMD9LSAMD9L*Age at HCT, years2.11.8Interval from diagnosis to HCT, years0.50.5Indication for HCTMDSMDSSignificant pretransplant issuesOtitis media, croup, roseolaAlpha hemolytic streptococcal sepsisDonor typeUnrelated, 10/10 allele match, female, bone marrowUnrelated, 10/10 allele match, female, bone marrowConditioning regimen; GVHD prophylaxisBu/Cy; Tac/MtxBu/Cy; Tac/MtxConditioning intensity (MA / RIC)MAMANeutrophil engraftment, days+199Platelet engraftment, days+1712Posttransplant courseUneventfulVOD of liver, hemolysis, coagulopathyIntensive careNoVODAcute GVHD / Chronic GVHDYes (Grade II, skin, gut, resolved) / Yes skin, mildNo / NoChimerism100% donor100% donorPost-HCT hematologic outcomeNormal blood counts, no monosomy 7, resolution of MDSNormal blood counts, no monosomy 7, resolution of MDSSurvival statusAlive; 5.3 y post-HCTAlive; 1.3 y post-HCTCurrent health statusDoing wellDoing well[^5]

Post-transplant complications included pericardial effusions (n = 3), veno-occlusive disease of liver (n = 3), thrombotic microangiopathy (n = 2), and diffuse alveolar hemorrhage (n = 1). Unique complications in several MIRAGE syndrome cases included large volume stool losses with dehydration and electrolyte imbalance, temperature and blood pressure instability, and hypoxia. Eight patients required transfer to intensive care for management of respiratory failure (n = 5), sepsis (n = 1), and severe hypertension (n = 1) and VOD of liver (n = 1).

One patient with a familial *SAMD9L* mutation, MDS, (patient 7, [Table 3](#tbl0003){ref-type="table"}) and morbid obesity failed to engraft following reduced-intensity conditioning with double unrelated cord blood transplantation. All other patients achieved neutrophil and platelet engraftment at a median of 16 days (range, 12 to 19; n = 11) and 17 days (range, 12 to 40; n = 10) post-HCT, respectively. Two patients developed grade II to III acute GVHD, which resolved with treatment. Two patients developed mild skin chronic GVHD. Two patients have chronic lung disease, and 2 other patients have chronic kidney disease. One patient with *SAMD9L* mutation and MDS (patient 7, [Table 3](#tbl0003){ref-type="table"}) with failed engraftment subsequently developed AML and died of its treatment complications. A second patient, with *SAMD9L* mutation and MDS (patient 10, [Table 3](#tbl0003){ref-type="table"}), died of diffuse alveolar hemorrhage while receiving defibrotide for treatment of veno-occlusive disease of liver. Immune reconstitution data are summarized in [Table 4](#tbl0004){ref-type="table"} .Table 4Summary of Available Clinical Data on Immune ReconstitutionTable 10Patient No.Characteristic12563481112Gene mutation*SAMD9SAMD9SAMD9SAMD9SAMD9SAMD9SAMD9LSAMD9LSAMD9L*MIRAGE phenotypeYesYesYesYesNoNoNoNoNoLymphocyte enumeration1 month post-HCT ALC per cumm570678470252924546288NA15122 months post-HCT ALC per cumm1970100013208642368240826NA1123 months post-HCT ALC per cumm208013071650NDND1125410NA370 CD3 per cumm375891NDNDNDNDNDNANA CD4 per cumm250369NDNDNDNDNDNANA CD8 per cumm83486NDNDNDNDNDNANA NK cells per cumm520167NDNDNDNDNDNANA CD19 per cumm1145249NDNDNDNDNDNANA Serum IgG, mg/dL1231120519822ND395NDNANA6 months post-HCT ALC per cumm250084046301254ND544935980981 CD3 per cumm11507262224390NDNDNDND451 CD4 per cumm6003081308277NDNDNDND216 CD8 per cumm50037782886NDNDNDND212 NK cells per cumm900114916193NDNDNDND193 CD19 per cumm45001264662NDNDNDND337 Serum IgG, mg/dL346254915752522218ND38952112 months post-HCT ALC per cumm6100180182001938ND770222014904070 CD3 per cumm384199962321212NDNDND13562426 CD4 per cumm18294953526737NDNDND3741548 CD8 per cumm18904592460362NDNDND884829 NK cells per cumm549185656178NDNDND97422 CD19 per cumm16466171148502NDNDND1271121 Serum IgG, mg/dL759623371ND300841351NA[^6][^7]

Ten of 12 patients were alive with a median follow-up of 3.1 years (range, 0.1 to 14.7 years). All surviving patients (n = 10) at time of last follow-up had resolution of hematologic disorder, had no chromosome 7 abnormalities, and sustained peripheral blood donor chimerism (90% to 100%). All patients were thriving. *SAMD9* cases had varying degrees of developmental delays (n = 6) and chronic kidney disease (n = 3). All patients with clinical characteristics of MIRAGE syndrome (n = 4) were short for age, required supplemental feeds, and had persistent adrenal insufficiency. In *SAMD9L* cases (n = 4), no clinical neurologic manifestations have been observed so far.

DISCUSSION {#sec0004}
==========

In this report, we describe transplant details and outcomes in a series of patients with hematologic diseases associated with *SAMD9/SAMD9L* germline mutations. We found that most patients underwent transplantation for MDS with chromosome 7 abnormalities and received myeloablative conditioning with HCT from nonsibling donor graft sources. Allogeneic HCT led to successful resolution of MDS or marrow failure, with sustained donor chimerism and excellent survival.

On review of literature, we found 10 other cases with *SAMD9* mutation who underwent HCT. A 4-year-old child with MIRAGE syndrome and monosomy 7 MDS underwent transplantation with active AML and died of Epstein-Barr virus-related lymphoproliferative disorder a year later [@bib0004]. Wilson and colleagues [@bib0021] reported a patient with MIRAGE syndrome who underwent reduced-intensity conditioning and unrelated donor HCT that led to resolution of monosomy 7 MDS. Sarthy et al. [@bib0014] described a patient with marrow failure and another patient with MDS who had severe MIRAGE phenotypes and underwent HCT after reduced-intensity conditioning. Comorbidities, including enteropathy, electrolyte imbalances, adrenal crises, bacteremia, and lung disease, significantly led to a complicated transplant course and ultimately death in both cases. Although transplant details in 6 other cases are limited, 1 patient without the MIRAGE phenotype died of unknown cause, and 5 were surviving following HCT [@bib0007], [@bib0010]. There were 4 cases of MIRAGE syndrome in our series. Before transplant, 3 of 4 cases had chronic diarrhea, malnutrition, and adrenal insufficiency. Post-HCT, we observed severe gastrointestinal fluid losses, electrolyte imbalance, and acute dehydration in these 3 cases. Whether such dramatic stool losses without an infectious etiology were secretory and whether autonomic instability could have contributed are unknown. Patients also experienced temperature and blood pressure instability, respiratory distress, and acute renal dysfunction.

Several of these medical issues are similar to those reported in the report by Sarthy et al. [@bib0014]. Despite a complicated acute transplant course, all 4 patients with MIRAGE syndrome in our series survived.

We observed a high rate of ongoing medical issues in MIRAGE syndrome transplant survivors. These include adrenocortical insufficiency, diarrhea, need for supplemental nutrition, and developmental delays. Patients with pre-existing lung disease and nephropathy continue to have these issues following HCT. Most of these issues are related to pre-existing MIRAGE syndrome manifestations. The transplant survivor reported by Wilson et al. [@bib0021] had ongoing medical issues of adrenocortical insufficiency, growth and developmental delays, and chronic lung and chronic kidney diseases.

In this series, all 6 *SAMD9L* patients had cytopenias and MDS with chromosome 7 abnormalities. We did not observe ataxia, incoordination, or other neurologic manifestations before or following transplant. On review of the literature, we found 11 additional cases of patients with *SAMD9L* mutations who had undergone HCT [@bib0005], [@bib0007], [@bib0011]. Although transplant details are limited, 2 patients died of complications (cerebral hemorrhage and infection, 1 each), 1 had unknown survival status, and 8 were alive. Of the surviving patients, 1 had pulmonary fibrosis, and 3 had neurologic issues.

Mutations in *SAMD9* and *SAMD9L* add to a growing list of recently described heritable conditions associated with cytopenias, marrow failure, MDS, and AML [@bib0001], [@bib0007], [@bib0008]. Although these patients can be managed symptomatically with transfusions and treatment of infections, the only curative treatment is with allogeneic HCT.

Indications and timing of HCT in these patients are not straightforward because marrow cells can undergo somatic genetic correction events and spontaneous blood count recovery [@bib0004], [@bib0008], [@bib0012], [@bib0022]. In our series, there was an interval of several years from initial presentation to development of bone marrow failure or MDS in 2 cases. Most patients in our series underwent transplantation for MDS with transfusion dependence, and a diagnosis of *SAMD9/SAMD9L* was made retrospectively from archived specimens. Affected siblings of patients who underwent transplantation have been followed without transplant; however, these are anecdotal case reports, and long-term data are needed [@bib0008], [@bib0011].

Patients who have relatively stable blood counts and do not show signs of development of MDS or AML may continue to be closely observed. However, in our view, patients who develop significant marrow failure (including if clinically symptomatic with infections, anemia, bleeding, and/or transfusion dependence), meet morphologic criteria of MDS, develop monosomy 7 or 7q-, or develop other cytogenetic abnormalities associated with myeloid malignancies should be evaluated for allogeneic HCT. Any potential family donors must undergo genetic evaluation for *SAMD9/SAMD9L* mutation as well.

In conclusion, in this small series of patients, we found that most patients with *SAMD9/SAMD9L* mutations tolerated transplant conditioning, with a high rate of engraftment and resolution of MDS or marrow failure. Clinically significant comorbidities were common in MIRAGE syndrome cases and contributed to unique adverse events in the acute post-transplant phase. These patients continue to require ongoing management and multispecialty care for syndrome-related nonhematologic manifestations.

More data are needed to define timing of HCT in *SAMD9/SAMD9L* patients and further refine conditioning regimens as well as management of patients with significant syndrome-related comorbidities. National and international transplant registries should be queried to examine reported outcomes in larger patient cohorts. Finally, long-term follow-up and care guidelines are needed for the survivors.
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[^1]: Abbreviations: Chr. 7 (chromosome 7); FSGS (Focal sclerosing glomerulosclerosis); HCT (hematopoietic cell transplantation); HLH (hemophagocytic lymphohistiocytosis); MDS (myelodysplastic syndrome); MIRAGE syndrome (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy); and, UPD (uniparental disomy)

[^2]: Abbreviations: WES indicates whole exome sequencing; WGS, whole genome sequencing; BMT, blood and marrow transplantation; ACMG, American College of Medical Genetics, and VUS, variant of unknown significance; NGS, Next generation sequencing.

[^3]: Each pathogenic criterion was weighted as very strong (PVS1), strong (PS1--4); moderate (PM1--6) or supporting (PP1--5) and each benign criterion was weighted as stand-alone (BA1), strong (BS1--4) or supporting (BP1--6). From Richards et al, [@bib0020].

[^4]: The *SAMD9* variant c.3406G\>C (p.E1136Q) was classified as a VUS using strict ACMG criteria. We believe this variant is pathogenic based on well-established functional data from two separate experimental studies showing that it has a deleterious effect on cells. The younger sibling of the patients above also carries the variant and had transient neonatal thrombocytopenia requiring transfusion. However, the mother of these patients carries the variant as well and presently lacks an apparent phenotype. Whether she was transiently affected in the past is unknown, but this is possible as somatic revertant mosaicism is a known associated phenomenon with *SAMD9/SAMD9L* variants. Other potential mechanisms that could account for the lack of phenotypic segregation include monoallelic gene expression, incomplete penetrance, or variable expressivity. We feel this is important to note for clinical reasons in case this variant is observed in another patient.

[^5]: Abbreviations: ATG (anti-thymocyte globulin); Ara-C (cytosine arabinoside); BU (busulfan); BMI (body mass index); Chr. 7 (chromosome 7); CKD (chronic kidney disease); Cy (cyclophosphamide); CsA (cyclosporine A); GI (gastrointestinal); Flu (fludarabine); HLH (hemophagocytic lymphohistiocytosis); MA (myeloablative); MDS (myelodysplastic syndrome); Mel (melphalan); MIRAGE syndrome (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy); MMF (mycophenolate mofetil); Mtx (methotrexate); N.E. (not evaluable); RIC (reduced intensity conditioning); Tac (tacrolimus); TBI (total body irradiation); TMA (thrombotic microangiopathy); and VOD (veno-occlusive disease)

[^6]: Patient 1 (*SAMD9* with MIRAGE): Protein-losing enteropathy. Intravenous immunoglobulin (IVIG) infusions. Patient 2 (*SAMD9* with MIRAGE): Chronic diarrhea. Patient 3 (*SAMD9* without MIRAGE): Lymphocyte enumeration 3 years post-HCT, ALC 4555, CD3 3160, CD4 1330, CD8 1610, NK cells 480, CD19 740, all in per cumm. Patient 4 (*SAMD9* without MIRAGE): Lymphocyte enumeration 3 years post-HCT, ALC 3700, CD3 2530, CD4 1090, CD8 1140, NK cells 400, CD19 770, all in per cumm. Patient 5 (*SAMD9* with MIRAGE): IVIG infusions monthly until 1 year post-HCT. Patient 6 (*SAMD9* with MIRAGE): IVIG infusions monthly until 6 months post-HCT. Patient 7 (*SAMD9L*): Not included in the table. ALC 286 on day +60. Graft failure. Patient 8 (*SAMD9L*): Lymphocyte enumeration 5 years post-HCT, ALC 3600, CD3 2630, CD4 1200, CD8 1310, NK cells 120, CD19 810, all in per cumm. Patient 9 (*SAMD9L*): Not included in the table. Underwent HCT 14 years ago. Data not available. Patient 10 (*SAMD9L*): No data. The patient died of transplant complications on day +23. Patient 11 (*SAMD9L*): Intermittent IVIG infusions. Patient 12 (*SAMD9L*): Intermittent IVIG infusions.

[^7]: ALC indicates absolute lymphocyte count; ND, not done; NK, natural killer; IgG, immunoglobulin G.
